Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17559745rdf:typepubmed:Citationlld:pubmed
pubmed-article:17559745lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:17559745lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:17559745lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:17559745lifeskim:mentionsumls-concept:C0681024lld:lifeskim
pubmed-article:17559745lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:17559745pubmed:issue7lld:pubmed
pubmed-article:17559745pubmed:dateCreated2007-7-19lld:pubmed
pubmed-article:17559745pubmed:abstractTextFew data are available on the economics of target therapy or refractory non-small-cell lung cancer (NSCLC).lld:pubmed
pubmed-article:17559745pubmed:languageenglld:pubmed
pubmed-article:17559745pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17559745pubmed:citationSubsetIMlld:pubmed
pubmed-article:17559745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17559745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17559745pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17559745pubmed:statusMEDLINElld:pubmed
pubmed-article:17559745pubmed:monthJullld:pubmed
pubmed-article:17559745pubmed:issn1473-4877lld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:MonnetIsabell...lld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:VergnenegreAl...lld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:RobinetGilles...lld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:PerolMauriceMlld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:FournelPierre...lld:pubmed
pubmed-article:17559745pubmed:authorpubmed-author:ChouaidChrist...lld:pubmed
pubmed-article:17559745pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17559745pubmed:volume23lld:pubmed
pubmed-article:17559745pubmed:ownerNLMlld:pubmed
pubmed-article:17559745pubmed:authorsCompleteYlld:pubmed
pubmed-article:17559745pubmed:pagination1509-15lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:meshHeadingpubmed-meshheading:17559745...lld:pubmed
pubmed-article:17559745pubmed:year2007lld:pubmed
pubmed-article:17559745pubmed:articleTitleEconomic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.lld:pubmed
pubmed-article:17559745pubmed:affiliationInserm unit U707, APHP, Paris, France. christos.chouaid@sat.ap-hop-paris.frlld:pubmed
pubmed-article:17559745pubmed:publicationTypeJournal Articlelld:pubmed